Homepage - CRTOnline

TAVR-in-TAVR

TAVR-in-TAVR

COVID-19 Outbreak Effects Seen in Cath Labs

COVID-19 Outbreak Effects Seen in Cath Labs

SCAI Cancels 2020 Scientific Sessions

SCAI Cancels 2020 Scientific Sessions

TVT Registry Confirms Safety of TAVR in Bicuspid Patients

TVT Registry Confirms Safety of TAVR in Bicuspid Patients https://www.crtonline.org/news-detail/tvt-registry-confirms-safety-of-tavr-in-bicuspid-p

No Increased Mortality with Paclitaxel DCBs in Coronaries

No Increased Mortality with Paclitaxel DCBs in Coronaries https://www.crtonline.org/news-detail/no-increased-mortality-with-paclitaxel-dcbs-in-cor

Trending Now More »
Alirocumab Reduces LDL-C in Homozygous FH

Mar 30, 2020 by
Chava Chezar-Azerrad and Jason Wermers, CRTonline.org

In patients with homozygous familial hypercholesterolemia (HoFH), treatment with the PCSK9 inhibitor alirocumab was found to significantly reduce low-density lipoprotein cholesterol (LDL-C) levels, as well as other atherogenic lipids and lipoproteins, according to study results presented Monday at the American College of Cardiology Scientific Sessions 2020 virtual conference.

Evinacumab Lowers LDL-C in Homozygous FH

Mar 30, 2020 by
Chava Chezar-Azerrad and Jason Wermers, CRTonline.org

Treatment with evinacumab, an ANGPTL3 inhibitor, in patients with homozygous familial hypercholesterolemia (HoFH), was found to be effective in lowering low-density lipoprotein cholesterol (LDL-C) levels independent of LDL receptor, according to late-breaking trial results presented Monday at the American College of Cardiology Scientific Sessions 2020 virtual conference.

Mavacamten Improves Biomarkers of Myocardial Wall Stress, Injury in Non-Obstructive HCM

Mar 30, 2020 by
Brian C. Case, CRTonline.org

A first-in-class reversible inhibitor of cardiac-specific myosin, mavacamten (mana, MyoKardia Inc.), was associated with significant reductions in N-terminal-pro hormone BNP (NT-proBNP) and cardiac troponin (cTnI), suggesting improved wall stress and reduced myocardial injury in non-obstructive hypertrophic cardiomyopathy (nHCM), according to study results presented Monday at the American College of Cardiology Scientific Sessions 2020 virtual conference.

Edoxaban, Warfarin Show Similar Thromboembolic, Bleeding Prevention After Bioprosthetic Valve Procedures

Mar 30, 2020 by
Jason Wermers, CRTonline.org

The direct oral anticoagulant edoxaban was shown to be noninferior to warfarin in preventing thromboembolism and major bleeding in the first 3 months after surgical bioprosthetic valve implantation or repair, according to study results presented Monday at the American College of Cardiology Scientific Sessions 2020 virtual conference.

10 Years Later, Study Shows Similar Outcomes Between CABG, PCI in Patients with Unprotected Left Main Disease

Mar 30, 2020 by
Brian C. Case, CRTonline.org

In the longest randomized controlled trial to compare drug-eluting stents and coronary artery bypass grafting (CABG) in patients with unprotected left main coronary artery (LMCA) disease, there were no significant differences in the rates of major adverse cardiac or cerebrovascular events, serious composite outcomes, and mortality over 10 years.

Despite More Complex Anatomy, New MitraClip Devices Show More MR Reduction

Mar 30, 2020 by
Brian Forrestal, CRTonline.org

The latest generation of MitraClip devices offers improved reductions in mitral regurgitation (MR) severity at 30 days compared to previous devices, according to study results presented Monday at the American College of Cardiology Scientific Sessions 2020 virtual conference.

Radial Gets a Boost in the OR, Too

Mar 30, 2020 by
Brian Forrestal, CRTonline.org

Patients who underwent coronary artery bypass grafting (CABG) with radial artery grafts showed improved survival and a lower rate of adverse cardiovascular events in comparison with those who underwent bypass surgery with saphenous vein grafts, according to late-breaking trial results presented Monday at the American College of Cardiology Scientific Sessions 2020 virtual conference.

3 Trials Confirm Ticagrelor Reduces Bleeding, Does Not Increase Thromboembolic Events vs. DAPT

Mar 30, 2020 by
Evan Shlofmitz and Jason Wermers, CRTonline.org

Three key late-breaking clinical trials confirmed that ticagrelor without aspirin following percutaneous coronary intervention (PCI) lowers bleeding risk and does not raise thromboembolic risk in comparison with ticagrelor-plus-aspirin therapy across several different types of patients, according to results presented Monday at the American College of Cardiology Scientific Sessions 2020 virtual conference.

Eicosapentaenoic Acid Appears to Drive Icosapent Ethyl’s Cardiovascular Risk Reduction

Mar 30, 2020 by
Jason Wermers, CRTonline.org

The striking reduction in cardiovascular disease risk associated with icosapent ethyl (IPE) seen in the REDUCE-IT trial appears to be the work of the omega-3 fatty acid eicosapentaenoic acid (EPA), according to late-breaking trial results presented Monday at the American College of Cardiology Scientific Sessions 2020 virtual conference.

Study: Renal Denervation Lowers Blood Pressure Without Medication

Mar 29, 2020 by
Charan Yerasi, crtonline.org

Catheter-based renal denervation is effective in reducing blood pressure in the absence of antihypertensive medications, according to late-breaking trial results presented Sunday at the American College of Cardiology Scientific Sessions 2020 virtual conference.

How Long To Continue Aspirin After ACS/PCI In Patients With Atrial Fibrillation? Insights From AUGUSTUS

ACC 2020 Late-Breaking Trials View All Slides

Relationships of Ischemia Severity and Coronary Artery Disease Extent with Clinical Outcomes in the ISCHEMIA Trial

Apr 03, 2020 by David Maron, MD

Clinical and Quality of Life Outcomes Across the Spectrum of Baseline Kidney Function Insights from the ISCHEMIA and ISCHEMIA-CKD Trials

Apr 03, 2020 by Sripal Bangalore, MD, MHA

A Composite Metric For Benchmarking Site Performance In Transcatheter Aortic Valve Replacement: Results From The STS/ACC TVT Registry

Mar 29, 2020 by Nimesh D. Desai MD PhD

Tailored Antiplatelet Initiation to Lessen Outcomes Due to Decreased Clopidogrel Response after Percutaneous Coronary Intervention

Mar 28, 2020 by Naveen Pereira

Rivaroxaban versus Enoxaparin in Non-Major Orthopedic Surgery

Mar 29, 2020 by Nadia Rosencher

Edoxaban versus Warfarin after Surgical Bioprosthetic Valve Implantation or Valve Repair

Mar 30, 2020 by Geu-Ru Hong, MD, PhD
In The News See More

Edoxaban, Warfarin Show Similar Thromboembolic, Bleeding Prevention After Bioprosthetic Valve Procedures

Mavacamten Improves Biomarkers of Myocardial Wall Stress, Injury in Non-Obstructive HCM

Evinacumab Lowers LDL-C in Homozygous FH

Alirocumab Reduces LDL-C in Homozygous FH

Radial Gets a Boost in the OR, Too

by
Brian Forrestal, CRTonline.org

COVID-19 Outbreak Effects Seen in Cath Labs

by
Jason Wermers, CRTonline.org

3 Studies Highlight Potential for Coronary Obstruction After TAVR

by
Jason Wermers, CRTonline.org

SCAI Cancels 2020 Scientific Sessions

by
Jason Wermers, CRTonline.org

Joint Statement from ACC Interventional Council and SCAI: COVID 19 and the Cardiac Cath Lab

by
Rebecca Torguson, CRTonline.org

DCB with PTX for SFA and below the risk latest data and usage in Europe

Latest Videos See All Interviews »

Update on the Intrepid System and the Apollo Trial

Mar 10, 2020

Non-Invasive Ultrasound Treatment of Calcific Aortic Stenosis

Mar 10, 2020

Stroke Intervention for the Interventional Cardiologist

Mar 10, 2020

The Artificial Papillary Muscle Concept in Mitral Prolaps

Mar 10, 2020

Anticoagulation for TAVR

Mar 10, 2020

Update on Magmaris Clinical Results and BIOSOLVE IV Results

Mar 10, 2020

Journal Watch More »
Bleeding risk, dual antiplatelet therapy, cessation, and adverse events after percutaneous coronary intervention. The PARIS Registry

Apr 03, 2020 by
S Sorrentino, et al.; Circ Cardiovasc Interv 2020; 13:e008226

Bleeding risk, dual antiplatelet therapy, cessation, and adverse events after percutaneous coronary intervention. The PARIS Registry

Trends in diest quality among youth in the United States, 1996-2016.

Apr 03, 2020 by
J Liu, et al.; JAMA 2020; 323:1161-74

Trends in diest quality among youth in the United States, 1996-2016.

Initial Invasive or Conservative Strategy for Stable Coronary Disease

Apr 03, 2020 by
D Maron, et al.; NEJM 2020 Online

Initial Invasive or Conservative Strategy for Stable Coronary Disease

Outcomes of Transcatheter Aortic Valve Replacement in Patients With Bicuspid Aortic Valve Disease. A Report From the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve The

Apr 03, 2020 by
Sharif A. Halim, et al.; Circ 2020; 141:1071-79

Outcomes of Transcatheter Aortic Valve Replacement in Patients With Bicuspid Aortic Valve Disease. A Report From the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry

Cardiovascular Marketplace More »
Transcatheter Mitral Valve Repair Coverage Decision Deadline Passes

Feb 19, 2020 by
CRTonline.org

Transcatheter Mitral Valve Repair Coverage Decision Deadline Passes

Tendyne Transcatheter Mitral Valve Gets CE Mark in Europe

Jan 30, 2020 by
CRTonline.org

Tendyne Transcatheter Mitral Valve Gets CE Mark in Europe

JenaValve Transcatheter Aortic Valve Replacement (TAVR) System Designated by FDA as Breakthrough Device

Jan 09, 2020
JenaValve Transcatheter Aortic Valve Replacement (TAVR) System Designated by FDA as Breakthrough Device

Vascepa Gets Coveted Event-Prevention Label

Dec 13, 2019 by
John Gever, Managing Editor, MedPage Today

Vascepa Gets Coveted Event-Prevention Label

Novartis to buy The Medicines Company for $9.7 Billion

Nov 25, 2019 by
CRTonline.org

Novartis to buy The Medicines Company for $9.7 Billion

CRT POLL

Do you feel safe in your hospital if a patient presented to the cath lab with possible or confirmed COVID-19 and needs a catheterization?

Yes

No

22%
Yes

78%
No

Show Results

1 2 3 4
1-5 of 16 results

Analysis of the Food and Drug Administration Manufacturer and User Facility Device Experience Database for Patient- and Circuit-Related Adverse Events Involving Extracorporeal Membrane Oxygenation

Mar 24, 2020 by
Nauman Khalid, Hasan Javed, Sarah Aftab Ahmad, J. James Edelman, Evan Shlofmitz, Yuefeng Chen, Anees Musallam, Toby Rogers, Hayder Hashim, Nelson L. Bernardo and Ron Waksman

Analysis of the Food and Drug Administration Manufacturer and User Facility Device Experience Database for Patient- and Circuit-Related Adverse Events Involving Extracorporeal Membrane Oxygenation

Are We Optimizing the Use of Dual Antiplatelet Therapy in Patients Hospitalized with Acute Myocardial Infarction?

Mar 24, 2020 by
Essa Hariri, Darleen Lessard, Joel Gore, Jeffrey Rade and Robert Goldberg

Are We Optimizing the Use of Dual Antiplatelet Therapy in Patients Hospitalized with Acute Myocardial Infarction?

Balloon-expandable transcatheter aortic valve replacement outcomes by procedure location: Catheterization laboratory versus operating room

Mar 24, 2020 by
Tom C. Nguyen, Patricia Keegan, Stephanie Nguyen, Pranav Loyalka, Tsuyoshi Kaneko, Pinak B. Shah, Kendra J. Grubb and Vasilis C. Babaliaros

Balloon-expandable transcatheter aortic valve replacement outcomes by procedure location: Catheterization laboratory versus operating room

Clinical Outcomes of the Dual-Therapy CD34 Antibody-Covered Sirolimus-Eluting Stent Versus Standard Drug-Eluting Coronary Stents: A Meta-Analysis

Mar 24, 2020 by
Paul Ndunda, Mohinder R. Vindhyal, Tabitha Muutu and Zaher Fanari

Clinical Outcomes of the Dual-Therapy CD34 Antibody-Covered Sirolimus-Eluting Stent Versus Standard Drug-Eluting Coronary Stents: A Meta-Analysis

Editorial: Misclassification of Type 2 Myocardial Infarction: Implications for Value-Based Programs and Quality Metrics

Mar 24, 2020 by
Jason H. Wasfy and Sean P. Murphy

Editorial: Misclassification of Type 2 Myocardial Infarction: Implications for Value-Based Programs and Quality Metrics

1 2 3 4
1-5 of 16 results

Early Experience With Cerebral Embolic Protection During Transcatheter Aortic Valve Replacement in the United States

Video Presentations All Presentations »

Long-Term Outcomes of Anticoagulation for Bioprosthetic Valve Thrombosis

Mar 12, 2020

TAVR Coiling Cases

Mar 05, 2020

Two rare complications of myocardial infarction: a case report

Mar 04, 2020

Axillary Artery Occlusion after TAVR

Mar 04, 2020

The Chaperone Technique

Jan 10, 2020

Duration of DAPT After PCI With DES

Dec 13, 2019

CRTonline on Facebook

CRT Meeting

CRTonline on Twitter

Tweets by @CRT_meeting

Explore the Site

Stay Connected

CRT Group Foundation is a not for profit corporation dedicated to providing educational services in the field of cardiology through the website, CRTonline.org and the Cardiovascular Research Technologies (CRT) annual symposium. CRT focuses on the advances and changes in the field of cardiovascular medicine. CRT is designed to provide access to the world’s leading clinicians and the latest research in order to improve practice and treatment outcomes for a variety of health care professionals.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details

* Required
* First Name:
* Last Name:
Member ID:
* Phone Number:
* Email:
* Enter code:

* Message:

TAVR-in-TAVR

COVID-19 Outbreak Effects Seen in Cath Labs

SCAI Cancels 2020 Scientific Sessions

TVT Registry Confirms Safety of TAVR in Bicuspid Patients

TVT Registry Confirms Safety of TAVR in Bicuspid Patients https://www.crtonline.org/news-detail/tvt-registry-confirms-safety-of-tavr-in-bicuspid-p

No Increased Mortality with Paclitaxel DCBs in Coronaries

No Increased Mortality with Paclitaxel DCBs in Coronaries https://www.crtonline.org/news-detail/no-increased-mortality-with-paclitaxel-dcbs-in-cor

Trending Now More »

ACC 2020 Late-Breaking Trials View All Slides

In The News See More

Latest Videos See All Interviews »

Journal Watch More »

Cardiovascular Marketplace More »

CRT POLL

Video Presentations All Presentations »

CRTonline on Facebook

CRTonline on Twitter

Explore the Site

Stay Connected

Thank you